| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $70.6M | — | — |
| R&D Expense | $86.3M | -0.4% | +24.7% |
| SG&A Expense | $24.3M | +20.3% | +68.8% |
| Operating Income | -$40.0M | +62.5% | +52.1% |
| Net Income | -$34.6M | +65.7% | +54.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $571.9M | -1.2% | -25.5% |
| Total Assets | $577.1M | -0.9% | -25.2% |
| Current Liabilities | $50.7M | -3.6% | +22.6% |
| Long-term Debt | $20.9M | +69.1% | +1.8% |
| Total Liabilities | $74.2M | +10.4% | +15.2% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$252.6M | — | — |
| Capital Expenditures | $255K | — | — |
| Investing Cash Flow | $301.9M | — | — |
| Financing Cash Flow | $20.8M | — | — |
| Free Cash Flow | -$252.9M | — | — |
| $503.0M |
| -2.4% |
| -28.9% |